NCT01227928 - Efficacy and Safety of Pazopanib Monotherapy After First-line Chemotherapy in Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Asian Women | Biotech Hunter

Enrollment

145

Participants

Timeline

Start Date

September 30, 2010

Primary Completion Date

October 31, 2012

Study Completion Date

January 31, 2014

Conditions

Neoplasms, Ovarian

Interventions

DRUG

Pazopanib

Pazopanib 800 mg daily for 24 months

DRUG

Placebo comparator

Placebo 800 mg daily for 24 months

Trial Locations (15)

104

GSK Investigational Site, Taipei

112

GSK Investigational Site, Taipei

100021

GSK Investigational Site, Beijing

100044

GSK Investigational Site, Beijing

100853

GSK Investigational Site, Beijing

110022

GSK Investigational Site, Shenyang

200032

GSK Investigational Site, Shanghai

210009

GSK Investigational Site, Nanjing

250012

GSK Investigational Site, Jinan

310006

GSK Investigational Site, Hangzhou

310022

GSK Investigational Site, Hangzhou

610041

GSK Investigational Site, Chengdu

Unknown

GSK Investigational Site, Guangzhou

GSK Investigational Site, Hong Kong

135-710

GSK Investigational Site, Seoul